Compass Therapeutics GC awarded 25,000 CMPX shares

Compass Therapeutics, Inc. reported that its General Counsel, Jonathan Anderman, received a grant of 25,000 shares of common stock at an award value of $1.89 per share as equity compensation.

Rhea-AI Filing Summary

Compass Therapeutics, Inc. reported that its General Counsel, Jonathan Anderman, received a grant of 25,000 shares of common stock at an award value of $1.89 per share as equity compensation. Following this grant, he holds 196,000 shares in total.

The filing notes that 150,000 of these shares are unvested restricted stock units granted on January 2, 2026. Each RSU converts into one share of common stock if service-based vesting conditions are met, vesting in four equal annual installments starting January 2, 2027.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Anderman Jonathan

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,000	$1.89	$47K

Holdings After Transaction: Common Stock — 196,000 shares (Direct)

Footnotes (1)

1. F1. 150,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.

Key Figures

Equity award size: 25,000 shares Award value per share: $1.89 per share Total shares after transaction: 196,000 shares +2 more

5 metrics

Equity award size 25,000 shares Common Stock grant to General Counsel

Award value per share $1.89 per share Grant/award acquisition price

Total shares after transaction 196,000 shares Holdings following reported award

Unvested RSUs 150,000 units RSUs granted January 2, 2026

RSU vesting schedule 4 equal annual installments Beginning January 2, 2027, service-based vesting

Key Terms

restricted stock units, RSU, service-based vesting conditions, Form 4

4 terms

restricted stock units financial

"150,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU financial

"Each RSU represents a contingent right to receive one share of common stock."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

service-based vesting conditions financial

"The award is subject to service-based vesting conditions and vests in four equal annual installments"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CMPX report for Jonathan Anderman?

Compass Therapeutics reported that General Counsel Jonathan Anderman received a grant of 25,000 shares of common stock at $1.89 per share. This was a compensation-related equity award, not an open-market purchase, and increased his total reported holdings to 196,000 shares.

How many Compass Therapeutics (CMPX) shares does Jonathan Anderman hold after this filing?

After the reported award, Jonathan Anderman holds 196,000 shares of Compass Therapeutics common stock. This total includes both vested shares and 150,000 unvested restricted stock units that may convert into shares if service-based vesting conditions are satisfied over time.

What are the terms of the 150,000 RSUs reported for CMPX’s General Counsel?

The filing states 150,000 shares are unvested restricted stock units granted January 2, 2026. Each RSU represents a right to receive one common share, vesting in four equal annual installments starting January 2, 2027, subject to service-based vesting conditions being met.

Was the CMPX insider transaction a market buy or a compensation grant?

The transaction was a compensation-related grant, not a market buy. The Form 4 labels the 25,000 CMPX shares with code “A” for grant, award, or other acquisition, and describes it as a grant/award acquisition rather than an open-market purchase of stock.

What role does Jonathan Anderman hold at Compass Therapeutics (CMPX)?

According to the filing, Jonathan Anderman serves as an officer of Compass Therapeutics with the title of General Counsel. The reported equity grant of 25,000 shares reflects part of his compensation, aligning his interests with the company’s long-term performance through stock-based awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 05:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderman Jonathan

(Last) (First) (Middle)

C/O COMPASS THERAPEUTICS, INC.

80 GUEST STREET, SUITE 601

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Compass Therapeutics, Inc. [ CMPX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026		A		25,000	A	$1.89	196,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 150,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.

	/s/ Neil Lerner attorney-in-fact	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)